In India, 61 million people have diabetes. By 2030, that number is expected to drastically increase, with more than 100 million Indians likely to develop the disease. In fact, the International Diabetes Federation estimates that 9.2 percent of adults in India have diabetes, making its prevalence second to that in China.
Responding to the country’s growing epidemic, Lilly India, in partnership with the Confederation of Indian Industry (CII) and Ministry of Health, hosted the inaugural National Non-Communicable Disease Summit last week in New Delhi.
Vice President for Asia Operations Jannie Oosthuizen and Managing Director of Lilly India Melt Van Der Spuy discuss the conference and first-of-their-kind initiatives taking place in the region.
The newly released white paper explores innovative approaches for diabetes prevention and management and highlights best practices and suggestions from a diverse range of experts, including stakeholders who participated in five roundtable forums in the state capitals. Van Der Spuy addressed the group and emphasized “Lilly’s ongoing commitment to the prevention and management of the disease as an essential element of fighting this growing epidemic.” Recommendations in the white paper are intended to strengthen the existing national policies and programs around diabetes management.
Here at Lilly, we are actively engaged in fighting NCDS – and diabetes specifically – not only through the medicines we make, but also through the Lilly NCD Partnership, in which the company is exploring new approaches to diabetes care in impoverished communities around the world. Lilly will also hold an upcoming NCD summit in South Africa as part of our partnership, continuing the momentum of last weekend’s NCD summit in India.